Phase 1A Study of the Safety of KSP/QRH Dimer

Phase 1

Completed

• Conditions: Healthy Adults
• Interventions: Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg; Drug: KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg

• Registration Number: NCT03643068
• Lead Sponsor: University of Michigan

Brief Summary

To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer) specific for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).

Detailed Description

This is a Phase IA study of the safety of an orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G) heptapeptide dimer for detection of neoplastic tissues in multiple areas of the gastrointestinal tract in humans. The investigators intend to enroll 25 evaluable subjects. The investigators expect to be able to enroll about 2-3 subjects per week, so the study should take about 2-3 months to complete.

Interested, healthy subjects ages 25-100 who respond to recruitment advertising on UMHealthResearch.org and appear to be eligible based responses to inclusion/exclusion criteria questions will be scheduled for a study visit at MCRU. At the study visit, the subjects will review and sign the informed consent and eligibility will be confirmed. If eligible, subjects will provide a blood sample for clinical labs and a urine sample for urinalysis, as well as have an EKG. A negative urine pregnancy test for women of child-bearing potential is required to be eligible. Eligible subjects will consume the reconstituted KSP-QRH-E3-IRDye800 (Peptide 919288G). After 5 minutes, subjects will drink a minimum 4-8 ounces of tap water and vital signs will be taken. Subjects will remain in MCRU for observation for 30 minutes. Vital signs will be recorded after 30 minutes, and another EKG will be conducted. Subjects are required to return to MCRU to have a repeat blood draw for clinical labs and urinalysis within 24 to 48 hours after KSP-QRH-E3-IRDye800 (Peptide 919288G) ingestion. The study team will conduct a verbal assessment for toxicity at this visit.

Study Timeline

• Study First Submitted: 2018-08-20
• Study First Submitted QC: 2018-08-20
• Study Start: 2018-08-22
• Study First Posted: 2018-08-22
• Primary Completion: 2018-10-27
• Study Completion: 2018-10-27
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-05
• Last Update Posted: 2018-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Not pregnant (willing to have pregnancy test if applicable)
• No recent illness (infection, URI, virus or flu) within 2 weeks,
• Stable health status (i.e. no medication changes within 2 months, no recent surgery, etc. per PI)
• Willing and able to sign informed consent
• Willing and able to drink the peptide and a tap water chaser
• Willing and able to get baseline and 24-48 hours post ingestion labs
• Willing and able to get pre and post ingestion EKG

Read More

Exclusion Criteria

• Known allergy to li-cor IRDye800CW, a near infrared fluorosphore or derivatives
• Subjects on active chemotherapy or radiation therapy
• Diabetics on insulin/hypoglycemic (due to fasting requirements)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3	KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg	The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25	KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg	Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.

Primary Outcome Measures

Name	Time	Method
Number of subjects with abnormal lab values	48 hours	review of laboratory values for abnormalities after intervention with KSP/QRH Dimer
Number of subjects with unexpected side effects	48 hours	Side effects collected through their follow-up visit

Trial Locations

Locations (1)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States